Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 26, 2021 /PRNewswire/ --
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans
Interim readout in ongoing Phase 1 trial finds...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials